Blueprint Medicines Corp (BPMC)
106.87
+1.41
(+1.34%)
USD |
NASDAQ |
May 15, 14:27
Blueprint Medicines Enterprise Value: 6.195B for May 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 14, 2024 | 6.195B |
| May 13, 2024 | 6.357B |
| May 10, 2024 | 6.273B |
| May 09, 2024 | 6.375B |
| May 08, 2024 | 6.403B |
| May 07, 2024 | 6.389B |
| May 06, 2024 | 6.245B |
| May 03, 2024 | 6.303B |
| May 02, 2024 | 6.291B |
| May 01, 2024 | 5.531B |
| April 30, 2024 | 5.311B |
| April 29, 2024 | 5.440B |
| April 26, 2024 | 5.433B |
| April 25, 2024 | 5.291B |
| April 24, 2024 | 5.387B |
| April 23, 2024 | 5.389B |
| April 22, 2024 | 5.283B |
| April 19, 2024 | 5.047B |
| April 18, 2024 | 5.176B |
| April 17, 2024 | 5.143B |
| April 16, 2024 | 4.999B |
| April 15, 2024 | 4.942B |
| April 12, 2024 | 5.072B |
| April 11, 2024 | 5.366B |
| April 10, 2024 | 5.256B |
| Date | Value |
|---|---|
| April 09, 2024 | 5.363B |
| April 08, 2024 | 5.321B |
| April 05, 2024 | 5.328B |
| April 04, 2024 | 5.268B |
| April 03, 2024 | 5.365B |
| April 02, 2024 | 5.323B |
| April 01, 2024 | 5.627B |
| March 31, 2024 | 5.529B |
| March 28, 2024 | 5.337B |
| March 27, 2024 | 5.332B |
| March 26, 2024 | 5.019B |
| March 25, 2024 | 4.930B |
| March 22, 2024 | 4.858B |
| March 21, 2024 | 5.042B |
| March 20, 2024 | 4.933B |
| March 19, 2024 | 4.915B |
| March 18, 2024 | 4.844B |
| March 15, 2024 | 5.070B |
| March 14, 2024 | 4.899B |
| March 13, 2024 | 5.076B |
| March 12, 2024 | 5.021B |
| March 11, 2024 | 5.007B |
| March 08, 2024 | 5.180B |
| March 07, 2024 | 5.164B |
| March 06, 2024 | 5.062B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.458B
Minimum
Nov 09 2022
6.403B
Maximum
May 08 2024
3.646B
Average
3.464B
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.222B |
| Apellis Pharmaceuticals Inc | 4.767B |
| Alnylam Pharmaceuticals Inc | 17.36B |
| Biomarin Pharmaceutical Inc | 15.17B |
| Corcept Therapeutics Inc | 2.469B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 89.14M |
| Revenue (Quarterly) | 96.12M |
| Total Expenses (Quarterly) | 174.94M |
| EPS Diluted (Quarterly) | 1.40 |
| Gross Profit Margin (Quarterly) | 96.68% |
| Profit Margin (Quarterly) | 92.74% |
| Earnings Yield | -4.50% |
| Normalized Earnings Yield | -7.043 |